Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · May 2016
Comparative StudyComparative effectiveness and safety of infliximab and adalimumab in patients with ulcerative colitis.
Real-world comparative benefits and risks of infliximab (IFX) and adalimumab (ADA) in patients with ulcerative colitis (UC) are unclear. ⋯ In a large retrospective cohort of patients with UC who were new users of anti-TNF agents, IFX-treated patients may have lower corticosteroid use than ADA-treated patients, but risk of hospitalisation and serious infections were comparable.